Latest Share Chat

REMOVE ADS

Hikma Pharmaceuticals Share News (HIK)

Hikma Pharmaceuticals Information

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes

Get Live Data

1,531.00 1.00 (0.07%)

Bid:

1,531.00

Ask:

1,532.00

Spread: 1.00 (0.065%)

Market Cap: £3.22b

Last checked at -

Intraday Hikma Pharmaceuticals Share Chart

REMOVE ADS

Hikma Pharmaceuticals News

LONDON BROKER RATINGS: Jefferies cuts Go-Ahead, Mediclinic to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Barclays downgrades Hikma to 'equalweight' on Generics concerns

(Sharecast News) - Barclays downgraded Hikma Pharmaceuticals on Friday to 'equalweight' from 'overweight' and cut the price target to 1,750p from 2,25...

LONDON BRIEFING: London Stock Exchange benefits from market volatility

(Alliance News) - London Stock Exchange Group on Friday said results in the first half of 2022 improved, as this year's interim period had an extra mo...

LONDON MARKET CLOSE: Stocks shrug off BoE's UK recession warning

(Alliance News) - Stocks in London managed to end higher on Thursday despite a bleak warning from the Bank of England regarding to outlook for the UK ...

LONDON MARKET MIDDAY: BoE hikes, expects UK recession in 4th quarter

(Alliance News) - London shares price made some gains on Thursday morning, though these fell well short of the market rise seen on mainland Europe, as...

Hikma revenue flat, profits tumble in first half

(Sharecast News) - Hikma shares were tumbling on Thursday morning after the pharmaceuticals company reported flat group revenue in its first half, at ...

LONDON MARKET OPEN: FTSE 100 underperforms amid pre-BoE trepidation

(Alliance News) - The FTSE 100 underperformed European peers and traded sideways in early dealings on Thursday, with the Bank of England to take centr...

TOP NEWS: Hikma first half hit by stiff competition for Generics

(Alliance News) - Hikma Pharmaceuticals PLC shares suffered on Thursday, as it lowered annual guidance after a poor performance in its Generics busine...